Researchers used AI to identify an mpox protein that triggers a strong immune response in mouse models. | Drug Discovery And ...

Public health officials have issued a high-alert warning as Ghana grapples with an uptick in Mpox fatalities and new infections just as the nation enters its busiest festive week.

Mpox (formally Monkeypox) is a viral disease caused by the Monkeypox virus and can infect both humans and animals. Interestingly, this is part of the viral family linked to smallpox. Patients that ...

SHELTON, CT / ACCESS Newswire / July 14, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of ...

A Phase II Clinical Trial Protocol has been developed with the Principal Investigator at this site in the Democratic Republic of Congo (DRC), and this Protocol is undergoing final refinements. A ...

Mpox is a viral disease usually transmitted from animals to humans and symptoms include fever and skin rashes. In 2023, a new ...

SHELTON, CONNECTICUT / ACCESS Newswire / July 16, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the ...

Emergent BioSolutions expects a 2024 net loss of $203 million-$183 million, down from the previous loss range of $314 million–$274 million. Emergent BioSolutions says its smallpox treatment to be ...

According to details surfaced on Saturday, both the patients, currently under treatment at Mayo Hospital, tested positive for ...

antiviral effectiveness of the drug in patients. The overall clinical trial will enroll approximately 80 patients. “This is an important milestone towards filing of the clinical trial application and ...

SHELTON, CT / ACCESS Newswire / July 1, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of ...

The MPox program enables advancing its pipeline towards revenue in the fastest possible manner, the Company believes. The Company intends to advance NV-387 against respiratory infections soon after ...